Tesamorelin: The GHRH Analogue With Real Trial Data Behind It
Tesamorelin is an FDA-approved GHRH analogue with strong trial evidence for reducing visceral fat in HIV-associated lipodystrophy, but off-label use rests on weaker ground.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Research Rats summary
Plain-English overview — free for everyone.
Tesamorelin is a GHRH analogue — it nudges the body to release its own growth hormone. It is an FDA-approved prescription medicine (sold as Egrifta), but only for one specific use: reducing excess abdominal fat in people with HIV-associated lipodystrophy.
Within that indication the evidence is genuinely strong — large, placebo-controlled randomised trials showed meaningful visceral-fat reduction. Outside it (general fat loss, anti-ageing, bodybuilding) there is essentially no trial evidence, and the benefit reverses once treatment stops.
It carries growth-hormone-class side effects and clear contraindications, it is prohibited in sport, and non-pharmacy 'research' tesamorelin is not the approved Egrifta product — its purity, dose accuracy and identity are unknown.
At a glance
- Compound class
- GHRH analogue (growth-hormone-releasing factor)
- Primary pathway / target
- GHRH receptor → pulsatile growth hormone → IGF-1
- Main research interest
- Visceral-fat reduction in HIV lipodystrophy; off-label body composition and anti-ageing
- Regulatory status
- Approved — specific indication
Evidence signals
shown separately — never one score
Community signal reflects how much a compound is discussed online — not how strong the evidence is.
- Common online interest
- Off-label fat loss, body recomposition, anti-ageing
- Major caution themes
- GH-class effects (oedema, joint pain)Insulin sensitivityContraindicated in malignancy/pregnancyProhibited in sportGrey-market ≠ Egrifta
Research Rats interpretation
Genuinely proven for one narrow, supervised indication (HIV-associated lipodystrophy). The popular off-label uses are extrapolation, the benefit reverses on stopping, and grey-market 'research' product is not the approved medicine.
Evidence gap
The strong evidence comes almost entirely from HIV-associated lipodystrophy; use for general fat loss, non-HIV fatty liver, or anti-ageing is extrapolation with no trial support. Long-term cardiovascular benefit is not established, and the effect reverses after stopping.
This page helps interpret evidence. It does not provide dosing, protocol, reconstitution, injection, sourcing, stack, cycle, suitability, or medical advice.
Evidence profile
Assessed 2026-06-13FDA-approved with strong, consistent trial evidence — but only for HIV-associated lipodystrophy; off-label use is unproven, the benefit is not durable, and GHRH analogues are WADA-prohibited.
Well-established GHRH→GH→IGF-1 axis; amplifies pulsatile GH rather than supplying exogenous GH.
Supported, though the evidence base is defined by its human trial programme.
Two pivotal Phase 3 RCTs (n=806) plus meta-analysis; FDA-approved for HIV lipodystrophy.
Clinically meaningful and proven — but only for HIV-associated lipodystrophy; off-label benefit unproven.
Well-characterised: FDA label, trial AE data and clear contraindications.
Approved / established (Egrifta, FDA 2010).
High confidence for the approved indication; off-label use is extrapolation.
Prescription-only approved drug, but WADA-prohibited (S2); grey-market ‘research’ product is not the approved Egrifta.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
An FDA-approved GHRH analogue with strong, consistent randomised evidence — but only for HIV-associated lipodystrophy; off-label anti-ageing/body-composition use is unproven, and the benefit reverses on stopping.
Safety snapshot
A well-characterised approved drug with a GH-class side-effect profile (arthralgia, oedema, possible reduced insulin sensitivity) and clear contraindications; grey-market 'research' product is not the approved Egrifta.
Regulatory & legality
Approved — specific indicationApproved for a specific indication only and WADA-prohibited; off-label use is unsupported, and the realistic non-pharmacy supply is grey-market.
Where claims can exceed the evidence
Proven and meaningful for HIV-associated lipodystrophy, not for the popular optimisation uses; the evidence does not extrapolate to other populations.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Tesamorelin is one of the few compounds in the "research peptide" world that has genuinely earned the label of a proven drug. It is an FDA-approved prescription medicine — sold as Egrifta — cleared in November 2010 for reducing excess abdominal fat in people with HIV-associated lipodystrophy [11][12]. That approval rests on two large, multicentre, double-blind, placebo-controlled Phase 3 trials involving more than 800 randomised adults, plus 52-week extension data [1][2].
Two caveats matter up front. First, nearly all of this evidence comes from HIV-positive adults on antiretroviral therapy — not from healthy people, not from general "belly fat", and not from anti-ageing or bodybuilding use; those applications are off-label and far less studied. Second, the benefit is not durable: visceral fat re-accumulates within months of stopping [3].
Safety note
Tesamorelin is contraindicated per the FDA label in active malignancy (GH/IGF-1 may promote tumour growth), in pregnancy, and in anyone with disruption of the hypothalamic-pituitary axis — such as a pituitary tumour, pituitary surgery or radiation, or head trauma. It should be discontinued if a malignancy develops [12].
Two further points deserve weight. First, long-term cardiovascular benefit is explicitly not established, despite the favourable lipid changes [12] — and the benefit is not durable, so any gains imply indefinite, costly therapy [3]. Second, non-prescription "research peptide" tesamorelin is not the FDA-approved Egrifta product and may carry unknown purity, dosing, sterility and contamination risks.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
The full research report — members
- Mechanism Deep Dive
- Clinical / Human Evidence
- Preclinical Evidence
- Dose and Exposure Data
- Expert Commentary
- Community Interpretation
- Evidence Interpretation
- Research Gaps
- References
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
Sermorelin: The GHRH Peptide With a Real Clinical Record
A clear, evidence-first look at sermorelin (GHRH 1-29): what it is, what the human trials actually show, and where the anti-ageing hype outruns the data.
same mechanism
Ipamorelin: A Selective GH Secretagogue With Strong Theory and Thin Human Proof
Ipamorelin is a selective ghrelin-receptor agonist that reliably releases growth hormone in animals and humans, but its one human efficacy trial failed and it has no approved use.
same compound class
CJC-1295 Without DAC (Mod GRF 1-29): What the Evidence Actually Shows
A plain-English, evidence-first look at CJC-1295 without DAC: what it is, why its half-life is short, what the research does and does not show, and the real risks.
same regulatory context
CJC-1295 With DAC: The GHRH Analog That Made It to Human Trials
An evidence-first look at CJC-1295 with DAC: real human PK/PD data, how albumin-binding extends its half-life to days, and why development was halted.